Chokri Ben Lamine: Platelet Subpopulations and Targeted Therapies Across Evidence Levels
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Study Stage / Evidence Level – Platelet Subpopulation – Targeted Therapies
Reversible P2Y12 inhibitors (ticagrelor / cangrelor)
- Stage: Phase III (established clinical practice)
- PLATO trial – robust RCT evidence – guideline standard in ACS
- Highest level evidence (Class I recommendation in cardiology guidelines)
GPVI inhibitors (glenzocimab, revacept)
- Stage: Phase II clinical trials
- PCI studies – good safety (decreased bleeding)
- Efficacy signal modest – no reduction in MI yet
- Promising but NOT standard of care
PI3K inhibition (LY294002)
- Stage: Preclinical / experimental
- Mechanistic targeting only
- No clinical application currently
COX-2 targeting / aspirin adjustment
- Stage: Mixed clinical data (small trials / observational)
- No consistent benefit – not guideline recommended
- Conceptual explanation for aspirin resistance
Platelet–immune axis (VEGF / PDGF / αIIbβ3 in cancer)
- Stage: Early clinical / exploratory (e.g., APOLLO study)
- Signal for improved outcomes with ICI combinations
- Hypothesis-generating – not standard oncology practice
S100A8/A9 inhibitors (ABR-215757)
- Stage: Preclinical models
- Demonstrated decreased RP-driven thrombosis
- No human outcome trials yet
SGLT2 inhibitors (indirect platelet modulation)
- Stage: Phase III cardiovascular outcome trials (indirect evidence)
- Proven decreased CV events – platelet benefit inferred
- Not platelet-specific indication but clinically relevant
Summary hierarchy (very high yield)
Phase III / Standard: Ticagrelor / Cangrelor
Phase II / Emerging: GPVI inhibitors
Preclinical / Experimental:
- PI3K inhibitors
- S100A8/A9 inhibitors
Hypothesis / Mixed evidence:
- COX-2 targeting
- Platelet–immune modulation
Clinical pearl
- Only P2Y12 reversible inhibitors currently translate platelet subpopulation biology into routine practice.
- Everything else is precision medicine pipeline (future hematology/cardiology integration).”
Other posts featuring Chokri Ben Lamine on Hemostasis Today.
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge
-
Oct 19, 2026, 16:13Javier M. Floren: When Immune Cells Move With Their Environment